SPRB
Spruce Biosciences Inc

2,806
Loading...
Loading...
News
all
press releases
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +36.36% and +4.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates
Curis (CRIS) delivered earnings and revenue surprises of +65.83% and +14.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +16.67% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant...
Business Wire·9mo ago
News Placeholder
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...
Business Wire·10mo ago
News Placeholder
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...
Business Wire·11mo ago
News Placeholder
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...
Business Wire·1y ago
News Placeholder
Buy Rating Affirmed for Spruce Biosciences Amid Anticipated Positive Clinical Trial Outcomes and Strong Financial Position
Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Spruce Biosciences (SPRB Research Report). The associated price t...
TipRanks Financial Blog·1y ago
News Placeholder
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...
Business Wire·1y ago
News Placeholder
Spruce Biosciences Recognized as a Bay Area Best Place to Work
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...
Business Wire·1y ago

Latest SPRB News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.